Peppy vs. Precision Peptide Co: facility claims and drug approval

Disclosure: Peppy Care publishes this comparison of its own service. Public information checked October 22, 2026; no firsthand product testing. Seller statements are attributed, not independently certified.

The address precisionpeptideco.com redirected to Precision Research Labs during this review. The destination makes claims about cGMP-certified and FDA-audited facilities and describes a testing panel covering identity, purity, content, endotoxins, sterility, metals, and batch variation. It states research-use restrictions and distinguishes itself from a 503A pharmacy.

The redirect is an observed website behavior. This article does not infer corporate ownership, a legal name change, or the history of the two brands from that behavior alone. Nor did we independently inspect the facilities or verify each testing claim.

A claim about a facility concerns a different subject from approval of a finished medicine. To evaluate it, identify the facility, the activity, the applicable standard, and the supporting record. Do not assume that an audit reference means FDA reviewed every marketed product for a particular medical use.

Similarly, a long testing list describes analytical questions rather than patient outcomes. Identity and contaminant testing may be relevant to characterization, but they do not establish that a preparation improves a condition or is suitable for a particular person. Our FDA registration and approval guide explains why those regulatory categories should stay separate.

Peppy’s shipping policy describes an intake reviewed by a licensed provider and prescription transmission to a licensed compounding pharmacy if approved. That is a healthcare process, but it should not be presented as FDA approval of the resulting compounded medicine.

The FDA’s compounding guidance states that compounded drugs are not FDA-approved and do not undergo the same premarket review as approved drugs. A patient should therefore ask why a compounded preparation is proposed, whether an approved option could meet the need, and what evidence applies to the exact treatment. A competitor’s facility claims do not excuse Peppy from answering those questions.

For manufacturing or testing statements, record the named organization, scope, date, and underlying document. For medical care, record the clinician, dispensing pharmacy, exact medicine, clinical rationale, cost, and follow-up arrangements. Mark information that has not been verified rather than treating a badge or acronym as the missing evidence.

The FDA’s online-pharmacy checklist helps with the pharmacy portion, including state licensure and pharmacist access. The final choice should reflect the purpose of the transaction: research sourcing or medical assessment. Neither the observed domain redirect nor a claim about facility standards demonstrates that a research catalog is a substitute for a patient-specific prescription.